Primary and secondary treatment for Helicobacter pylori in the United States

Reviews in Gastroenterological Disorders

Volumn 5, Issue 2, 2005, Pages 67-72

  Vakil, Nimish ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Dyspepsia; Helicobacter pylori; Peptic ulcer disease

Indexed keywords

ALCOHOL; AMOXICILLIN; ANTIBIOTIC AGENT; BISMUTH; CLARITHROMYCIN; ESOMEPRAZOLE; FURAZOLIDONE; LANSOPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE BISMUTH CITRATE; RIFABUTIN; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; CLINICAL TRIAL; COST CONTROL; DIARRHEA; DRUG COST; DRUG DEGRADATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG TISSUE LEVEL; DYSPEPSIA; FECES ANALYSIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; PATIENT COMPLIANCE; PEPTIC ULCER; REVIEW; SENSITIVITY AND SPECIFICITY; STOMACH MUCOSA; TASTE DISORDER; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; UNITED STATES; UREA BREATH TEST;

ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; DRUG RESISTANCE, BACTERIAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; UNITED STATES;

EID: 21044444184     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Goddard A. Review article: factors influencing antibiotic transfer across the gastric mucosa. Aliment Pharmacol Ther. 1998;12:1175-1184.
2. Erah P, Goddard A, Barrett D, et al. The stability of amoxicillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother. 1997;39:5-12.
3. Sherwood P, Wibawa J, Atherton J, et al. Impact of acid secretion, gastritis and mucus thickness on gastric transfer of antibiotics in rats. Gut. 2002;51:490-494.
4. Goddard A, Jessa M, Barrett D, et al. Effect of omeprazole on the distribution of metronidazole, amoxicillin and clarithromycin in human gastric juice. Gastroenterology. 1996;111:358-367.
5. Gustavson LE, Kaiser JF, Edmonds AL, et al. Effect of omeprazole on gastric concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob Agents Chemother. 1995;39:2078-2083.
6. Pedrazzoli J, Calafatti S, Ortiz R, et al. Transfer of clarithromycin to gastric juice is enhanced by omeprazole in Helicobacter pylori-infected individuals. Scand J Gastroenterol. 2001;36: 1248-1253.
7. Laine L, Fennerty MB, Osato M, et al. Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. Am J Gastroenterol. 2000; 95:3393-3398.
8. Laine L, Suchower L, Frantz J, et al. Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials. Am J Gastroenterol. 1998;93:2106-2112.
9. Fennerty MB, Kovacs TO, Krause R, et al. A comparison of 10 and 14 days of lansoprazole triple therapy for eradication of Helicobacter pylori. Arch Intern Med. 1998;158:1651-1656.
10. Bochenek WJ, Peters S, Fraga PD, et al; Helicobacter pylori Pantoprazole Eradication (HELPPE) Study Group. Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies. Helicobacter. 2003;8:626-642.
11. Vakil N, Lanza F, Schwartz H, Barth J. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther. 2004;20:99-107.
12. Laine L, Hunt R, El-Zimaity H, et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol. 2003;98:562-567.
13. Laine L, Estrada R, Trujillo M, et al. Randomized comparison of differing periods of twice a day triple therapy for the eradication of Helicobacter pylori. Aliment Pharmacol Ther. 1996;10:1029-1033.
14. Vakil N, Cutler A. The efficacy of 10 day therapy with ranitidine bismuth citrate, clarithromycin and amoxicillin in the eradication of Helicobacter pylori. Am J Gastroenterol. 1999; 94:1197-1199.
15. Duck WM, Sobel J, Pruckler JM, et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis. 2004; 10:1088-1094.
16. Vakil N, Hahn B, McSorley D. Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States. Am J Gastroenterol. 1998;93:1432-1435.
17. Perez Aldana L, Kato M, Nakagawa S, et al. The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter. 2002; 7:306-309.
18. Houben M, van de Beek D, Hensen E, et al. A systematic review of Helicobacter pylori eradication therapy - the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther. 1999;13:1047-1055.
19. Graham DY, Lew GM, Malaty HM, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology. 1992;102:493-496.
20. Sharma VK, Howden CW. A national survey of primary care physicians' perceptions and practices related to Helicobacter pylori infection. J Clin Gastroenterol. 2004;38:326-331.
21. Broutet N, Tchamgoue S, Pereira E, et al. Risk factors for failure of Helicobacter therapy - results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther. 2003;17:99-109.
22. Vaira D, Vakil N, Menagatti M, et al. The stool antigen test for the detection of Helicobacter pylori after eradication therapy. Ann Intern Med. 2002;136:280-287.
23. Vakil N, Vaira D. Non-invasive tests for the diagnosis of H. pylori infection. Rev Gastroenterol Disord. 2004;4:1-6.
24. Vakil N, Rhew D, Sell A, Ofman J. The cost-effectiveness of diagnostic testing strategies for H. pylori. Am J Gastroenterol. 2000;95:1691-1698.
25. Lamouliatte H, Megraud F, Delchier JC, et al. Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. Aliment Pharmacol Ther 2003;18:791-797.
26. Wong WM, Gu Q, Lam SK, et al. Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol Ther. 2003;17:553-560.
27. Nista EC, Candelli M, Cremonini F, et al. Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment Pharmacol Ther. 2003;18:627-633.
28. Perri F, Festa V, Merta A, et al. Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy.' Aliment Pharmacol Ther. 2003;18:815-820.
29. Gatta L, Ricci C, Zullo A, et al. High eradication rate with a rescue levofloxacin based treatment for Helicobacter pylori [abstract 102244]. Paper presented at: Digestive Disease Week; May 15-20, 2004; New Orleans, La.
30. Best L, Cooper-Lesins G, Haldane D, et al. Helicobacter pylori antibiotic resistance in Canadian populations [abstract 105472]. Paper presented at: Digestive Disease Week; May 15-20, 2004; New Orleans, La.
31. Wong WM, Wong BC, Lu H, et al. One-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies. Aliment Pharmacol Ther. 2002;16:793-798.
32. Graham DY, Osato MS, Hoffman J, et al. Furazolidone combination therapies for Helicobacter pylori infection in the United States. Aliment Pharmacol Ther. 2000;14:211-215.